Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 5/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.81 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.81 |
| ▸ | HTR2B | P41595 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | BLM | P54132 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.81 |
| ▸ | MPO | P05164 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.81 |
| ▸ | NQO2 | P16083 | 1/20 | 0.81 |
| ▸ | RAB9A | P51151 | 1/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.81 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630306 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| SCHEMBL27084981 | 0.90 | MTNR1A (0.81) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL19018 | 0.90 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL8060688 | 0.90 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL4686085 | 0.90 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL29349848 | 0.90 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL28895534 | 0.89 | MTNR1A (0.97) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL8850894 | 0.89 | MTNR1A (0.97) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL29153193 | 0.89 | MTNR1A (0.97) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 | |
| Melatonin SCHEMBL28994307 | 0.89 | MTNR1A (0.97) | MTNR1AMTNR1BKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886642-A | Selenium-rich nutrient solution for tartary buckwheat production and application | 成都大学 | 2024-04-16 | — | — | CN | claimed |
| CN-117886642-A | Selenium-rich nutrient solution for tartary buckwheat production and application | 成都大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-112500412-B | Penamine A alkaloid structure simplification compound and application thereof | 中国人民解放军空军军医大学 | 2021-09-24 | — | — | CN | disclosed |
| CN-112500412-A | Penamine A alkaloid structure simplification compound and application thereof | 中国人民解放军空军军医大学 | 2021-03-16 | — | — | CN | disclosed |
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2004085392-A1 | MELATONIN DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL DYSFUNCTIONS | FAUST PHARMACEUTICALS (FR) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | MTNR1A 238/4885MTNR1B 339/4885KMT2A 2432/4885 |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | MTNR1A 40/4885MTNR1B 89/4885KMT2A 866/4885 |
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | MTNR1A 454/4885MTNR1B 756/4885KMT2A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.